In re Roundup Products Liability Litigation

Track this case

Case Number:

3:16-md-02741

Court:

California Northern

Nature of Suit:

Personal Inj. Prod. Liability

Multi Party Litigation:

Multi-district Litigation

Judge:

Vince Chhabria

Firms

Companies

Government Agencies

Sectors & Industries:

  1. May 26, 2021

    Judge Won't OK $2B Deal For Future Roundup Claims

    A California federal judge on Wednesday said he wouldn't approve a $2 billion settlement to cover future claims that Monsanto's weedkiller Roundup causes cancer, finding that while the deal does a lot for the Bayer AG unit, it has "tenuous" benefits for class members.

  2. May 19, 2021

    Judge Raises Litigation Risks, Doubts In $2B Roundup Deal

    The California federal judge overseeing the $2 billion settlement for future claims that Monsanto's weedkiller Roundup causes cancer said Wednesday he had serious concerns for consumers who have been exposed to the weedkiller but have not yet been found to have cancer, especially the potential for the U.S. Supreme Court to wipe out their claims.

  3. April 02, 2021

    National Black Farmers' Roundup Suit To Stay In Calif. MDL

    The Judicial Panel on Multidistrict Litigation will not reconsider its decision to transfer into a California MDL a suit by the National Black Farmers Association against Monsanto aiming to stop the sale of the weedkiller Roundup.

  4. March 08, 2021

    Attys Seek To Delay $2B Roundup Deal Hearing

    Counsel for the proposed class of future Roundup claimants and Bayer AG's Monsanto on Sunday asked a California federal judge to push back a hearing on a $2 billion settlement offer to May so they have more time to address recent objections to the deal.

  5. March 05, 2021

    Roundup Claimants Slam 'Frankenstein-ian' $2B Bayer Deal

    Hundreds of attorneys and several consumer and legal advocacy organizations on Friday joined dozens of putative class members in the Roundup product liability case in urging a California federal judge not to approve a proposed $2 billion deal to settle claims that the weedkiller causes cancer, saying the "anemic" settlement benefits Monsanto and its parent company Bayer AG more than sick plaintiffs.

  6. November 03, 2020

    Bayer Budgets $2B To Settle Future Roundup Cancer Claims

    Monsanto's parent company Bayer AG said Tuesday it expects to pay $2 billion in a class settlement to resolve future claims that Roundup weedkiller causes cancer, increasing its original estimate of $1.25 billion.

  7. September 15, 2020

    Bayer's Roundup Settlements Back On After 'Slight Hiccup'

    Cancer victims' counsel in multidistrict litigation over Monsanto's Roundup's alleged links to non-Hodgkin's lymphoma told a California federal judge Monday that they had reached "binding" settlements with Bayer AG following concerns last month that a previously announced $10.1 billion deal had fallen through.

  8. August 27, 2020

    Bayer's $10B Roundup Deal Teeters As Victims' Attys Cry Foul

    Cancer victims' counsel in multidistrict litigation over Roundup's alleged links to non-Hodgkin's lymphoma told a California federal judge Thursday that Monsanto hasn't followed through with its estimated $10 billion deal to settle the bulk of roughly 125,000 claims, while the company's counsel conceded "there are no final agreements."

  9. August 03, 2020

    Top Product Liability Cases Of 2020: Midyear Review

    Bayer's multibillion-dollar settlements over its weedkiller Roundup, herbicide dicamba and allegations over waterway contamination, as well as a $186 million verdict in favor of consumers who claimed that Johnson & Johnson talc products caused their cancer made Law360's list of the top product liability cases so far this year.

  10. July 28, 2020

    Bayer Wants Shareholder Suit Separate From Roundup MDL

    Bayer is urging a California federal court not to allow pension fund claims that it downplayed the significance of litigation over the weedkiller Roundup into wider multidistrict litigation involving claims that it causes non-Hodgkin's lymphoma, saying the disputes have "no meaningful overlap."